Nestlé boosts investment as Aimmune preps launch of peanut allergy drug

With $200 million more in the bank, the biotech also in-licensed an experimental next-generation food allergy therapy from Xencor. 

By Jonathan Gardner • Updated Feb. 5, 2020

Regeneron partners with US government to develop coronavirus treatment

The biotech hopes to replicate its past success in quickly advancing a treatment for Ebola. But, as that experience showed, proving a new antiviral isn't easy.

By Ned Pagliarulo • Updated Feb. 4, 2020

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

January price increases confirm slowing drug inflation

Pfizer, GlaxoSmithKline and Allergan were the most active, collectively raising list prices on some 450 drugs, according to one Wall Street analyst.

By Jonathan Gardner • Feb. 4, 2020

Bristol-Myers launches biotech targeting fibrosis, inflammation

Anteros Pharmaceuticals is the first company made via a partnership between Bristol-Myers and biotech accelerator BioMotiv. Its initial targets are liver and lung fibrosis, with one specific focus being IPF.

By Jacob Bell • Feb. 4, 2020

Commercial and regulatory strategy considerations for biotech

Discover ideas and insights for getting innovations in the biotech pipeline to patients sooner. 

By Alberto Grignolo, Corporate Vice President, Parexel; Sheela Hegde, Partner and Managing Director in Parexel’s Health Advances subsidiary; and Leslie DeVos, VP, Regulatory Consulting, Parexel • Feb. 3, 2020

FDA approves Aimmune drug as first treatment for peanut allergy

Aimmune's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.

By Jonathan Gardner • Jan. 31, 2020

Biotech lacking diverse leadership, top trade group admits

Too few women and people of color are in executive positions or on the boards of biotech companies, according to a new report from BIO. 

By Ned Pagliarulo • Jan. 31, 2020

Vertex impresses with strong Trikafta launch

With $420 million in fourth quarter revenues, Vertex's cystic fibrosis drug Trikafta performed five times better than expected — and capped off an eight-year growth story for the biotech's CEO.

By Jacob Bell , Ned Pagliarulo • Updated Jan. 31, 2020

With no Alzheimer's update, attention turns to Biogen's troubles

Spinraza competitors and Tecfidera patent challenges were in the spotlight as Biogen provided few details about its planned filing for aducanumab.

By Jacob Bell • Jan. 30, 2020

Big pharma backed away from brain drugs. Is a return in sight?

Biotech executives see a new era of neuroscience breakthroughs on the horizon. But in a historically challenging space, it's hard to pinpoint what would cause big pharma to dive back in — and what ripples that would create.​

By Jacob Bell • Jan. 29, 2020

Decibel CEO steps down as company pares workforce

The Third Rock-backed company put an acting executive in place as it repositions for development in gene therapy and regenerative medicine.

By Jonathan Gardner • Jan. 29, 2020

Pfizer lays out gene therapy aspirations

With more Phase 3 trials on the near horizon, the big pharma plans to add one new gene therapy project per year to its pipeline.

By Jonathan Gardner • Jan. 28, 2020

FDA decision nears on Aimmune's contested peanut allergy drug

Palforzia is one of two products under review by the FDA that are aimed at desensitizing people highly allergic to peanuts.

By Jonathan Gardner • Jan. 24, 2020

Epizyme drug granted approval by FDA for rare cancer

Five years after buying back rights from Eisai, Epizyme won approval for its first-ever drug. 

By Ned Pagliarulo • Updated Jan. 24, 2020

Roche strengthens case for SMA drug with new study data

Results showed the oral drug can help improve motor function in babies with the severest form of a rare degenerative muscular disease.

By Jonathan Gardner • Jan. 23, 2020

Safety risks highlighted in FDA letter on Sarepta's Vyondys

In rejecting Vyondys last August, one FDA official wrote that, without confirmatory trials for either of Sarepta's muscular dystrophy drugs, it's difficult to judge whether they're worth the risk.

By Jonathan Gardner • Jan. 22, 2020

Drug trial success a consolation prize for Akcea, Ionis

Although Novartis chose not to license Akcea and Ionis' high triglyceride drug, positive data could open up new development opportunities.

By Ned Pagliarulo • Jan. 22, 2020

5 biopharmas to watch as the decade's last earnings kick off

Biogen faces down analysts one more time on its aducanumab plans, while two biotechs could give early glimpses into their first-ever drug launches. 

By Ned Pagliarulo , Jacob Bell • Jan. 21, 2020

After big year, RNAi drugmakers compete to prove what comes next

"We are in the first out of the first inning of the lifespan of RNAi," said Arrowhead CEO Christopher Anzalone. Two RNAi drugs are now approved, but the field still has much to prove.

By Andrew Dunn • Jan. 17, 2020

BioNTech rescues cancer biotech Neon in bargain buyout

The all-stock deal, worth $67 million, valued Neon at a 86% discount to the cell therapy developer's IPO price of $16 per share.

By Ned Pagliarulo • Jan. 16, 2020

Orchard isn't for the picking, Biohaven's Allergan headache, and who's on Vascepa?

Amarin CEO John Thero had one question for investors eager to hear about his company's plans for its heart pill, while Orchard made a case for independence.

By Jacob Bell • Jan. 16, 2020

Nektar quickly drops opioid drug after FDA panel rejection

After a decade of research, the biotech said it will withdraw its application for oxycodegol and make no further investment in the drug.

By Kristin Jensen • Jan. 15, 2020

Galapagos finds a new normal at biotech's biggest dealmaking event

Though the Belgian drug company is tied to a 10-year, $5 billion research pact with Gilead, its CEO says there's still some "wheeling and dealing" left to do.

By Jacob Bell • Jan. 15, 2020

Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective

Roche, maker of the last decade's top cancer drugs, is betting that neuroscience R&D can make strides in the 2020s — an outlook that contrasts with research retreats by the pharma's peers. 

By Andrew Dunn , Jacob Bell • Jan. 15, 2020

Astellas swoops in for Adaptimmune deal a day after positive data

For $50 million, the Japanese pharma signed up for three programs in a deal that could net Adaptimmune hundreds of millions more if all goes to plan. 

By Jonathan Gardner • Jan. 14, 2020